Risk factors for breast cancer subtypes among Black women undergoing screening mammography
ConclusionOur results suggest that breast density and obesity are strong risk factors for TNBC among Black women. Understanding breast cancer subtype specific risk factors among Black women can help improve risk assessment. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research

Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy
ConclusionIn T1-2N1mi patients with mastectomy and SLNB, axillary recurrences were rare. No statistically significant differences were noted between patients with SLNB, ALND, or PMRT. Our findings suggest that these patients may be safely treated without axillary therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2021 Category: Cancer & Oncology Source Type: research

Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model
AbstractPurposeTo extend the functionality of the existing INFLUENCE nomogram for locoregional recurrence (LRR) of breast cancer toward the prediction of secondary primary tumors (SP) and distant metastases (DM) using updated follow-up data and the best suitable statistical approaches.MethodsData on women diagnosed with non-metastatic invasive breast cancer were derived from the Netherlands Cancer Registry (n = 13,494). To provide flexible time-dependent individual risk predictions for LRR, SP, and DM, three statistical approaches were assessed; a Cox proportional hazard approach (COX), a parametric spline ap...
Source: Breast Cancer Research and Treatment - August 2, 2021 Category: Cancer & Oncology Source Type: research

Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A   & gt;  G founder variant could be associated with higher male breast cancer risk
ConclusionWe observed a high mutation detection rate and conclude this may be due to the prevalentBRCA2:c.7806-2A  >  G variant in Slovenia. Our results indicate a possible association between this variant and higher risk of breast cancer in males compared to other identified P/LPVs inBRCA2. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 11, 2021 Category: Cancer & Oncology Source Type: research

Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors
AbstractPurposeTo determine the positive predictive value (PPV) of magnetic resonance imaging (MRI)-guided breast biopsy stratified by body mass index (BMI). Secondary endpoints include evaluation of indications for breast MRI and identification of factors associated with malignant biopsy.MethodsWe retrospectively analyzed results of MRI-guided breast biopsies in a consecutive cohort of women at a single institution between 2014 and 2019. The PPV was compared between BMI subgroups and the overall group by the one-samplez-test. Factors associated with malignant biopsy were analyzed using multivariate regression analysis.Res...
Source: Breast Cancer Research and Treatment - July 11, 2021 Category: Cancer & Oncology Source Type: research

Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer
ConclusionsHigh-RS was an independent risk factor for RR. The significantly higher RR rate of patients with both high-RS and clinical high-risk features compared with other groups suggests that this patient group can be a potential candidate for regional nodal irradiation. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 11, 2021 Category: Cancer & Oncology Source Type: research

DNA methylation and breast cancer-associated variants
We examined possible relationships between genetic variation, regulation, and expression to clarify the molecular alterations associated with these variants.MethodsGenome-wide methylomic variation was quantified (MethylationEPIC) in Asian breast cancer patients (1152 buffy coats from peripheral whole blood). DNA methylation (DNAm) quantitative trait loci (mQTL) mapping was performed for 235 of the 313 variants with minor allele frequencies  >  5%. Stability of identified mQTLs (p 
Source: Breast Cancer Research and Treatment - July 11, 2021 Category: Cancer & Oncology Source Type: research

Sanchez et al. respond to Austin-Datta et al.
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 11, 2021 Category: Cancer & Oncology Source Type: research

Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients
AbstractPurposeThe implementation of national breast cancer (BC) screening programs in Latin America has been rather inconsistent. Instead, most countries have opted for “opportunistic” mammogram screenings on the population at risk. Our study assessed and compared epidemiological, clinical factors, and survival rates associated with BC detected by screening (SDBC) or self-detected/symptomatic (non-SDBC) in Chilean female patients.MethodsRegistry-based cohort study that included non-metastatic BC (stage I/II/III) patients diagnosed between 1993 and 2020, from a public hospital (PH) and a private university canc...
Source: Breast Cancer Research and Treatment - July 10, 2021 Category: Cancer & Oncology Source Type: research

Symptoms associated with comorbid diabetes among breast cancer survivors
AbstractBackgroundThe symptoms experienced by women with diabetes overlap with those of women with breast cancer and diabetes can worsen breast cancer symptoms. Studying the impact of diabetes on symptoms experienced by women with breast cancer can contribute to assessment and intervention strategies and facilitate the management of symptoms in this patient population.MethodsWe analyzed data from a sample of 164 breast cancer patients in order to examine symptoms associated with comorbid diabetes. Data were collected by postal survey.ResultsA sizeable percentage of the women (23.8%) had a reported history of diabetes. Afri...
Source: Breast Cancer Research and Treatment - July 9, 2021 Category: Cancer & Oncology Source Type: research

Associations between frailty and cancer-specific mortality among older women with breast cancer
ConclusionAmong a cohort of older women with BC, higher degrees of frailty were associated with higher risk of all-cause mortality, but not BC-specific mortality. Future study should examine if preventing progression of frailty may improve all-cause mortality. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 9, 2021 Category: Cancer & Oncology Source Type: research

Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
ConclusionsOur results show that PEA15 phosphorylation status serves as an important regulator for PEA15 ’s dual role as an oncogene or tumor suppressor and support the potential of PEA15-AA as a therapeutic strategy for treatment of TNBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 9, 2021 Category: Cancer & Oncology Source Type: research

KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer
ConclusionWe conclude that KMT2C could serve as a potential biomarker of prognosis and chemotherapy sensitivity by affecting the DNA damage repair-related genes of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 8, 2021 Category: Cancer & Oncology Source Type: research

Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trial
ConclusionDeploying CCC in medical oncology practices was feasible, and the intervention content was acceptable. CCC shows promise for improving patient knowledge and patient –provider communication about provider roles in team-based cancer care and encouraging patients to engage with their PCP early in the survivorship period. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 7, 2021 Category: Cancer & Oncology Source Type: research

ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism
ConclusionZEB2 is a multi-functional regulator of drug sensitivity, cell migration, and metastasis in ER  + breast cancer and functions through non-canonical mechanisms. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 6, 2021 Category: Cancer & Oncology Source Type: research

Correction to: Factors associated with late risks of breast cancer ‑specific mortality in the SEER registry
The article “Factors associated with late risks of breast cancer‑specific mortality in the SEER registry”, written by José P. Leone, Carlos T. Vallejo, Michael J. Hassett, Julieta Leone, Noah Graham, Nabihah Tayob, Rachel A. Freedman, Sara M. Tolaney, Bernardo A. Leone, Eric P. Winer and Nancy U. Lin, wa s originally published electronically on the publisher’s internet portal on April 24, 2021 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on May 11, 2021 to © The Author(s) 2021 and the article is forthwith distributed unde...
Source: Breast Cancer Research and Treatment - July 6, 2021 Category: Cancer & Oncology Source Type: research

Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study
ConclusionOur findings indicate that there is no clear association between zinc and overall breast cancer risk or risk of different breast cancer subgroups. Finally, our results suggest that serum zinc is a poor marker of zinc intake. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 5, 2021 Category: Cancer & Oncology Source Type: research

Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer
ConclusionsA ML based pCR prediction model using pre-treatment clinical and pathological characteristics provided useful information to predict pCR during NAC. This prediction model would help to determine treatment strategy in patients with BC planned NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 5, 2021 Category: Cancer & Oncology Source Type: research

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
ConclusionsThe proposed ABC calculator is internally valid and can accurately predict disease outcomes. It may be used to predict patient prognosis, aid planning of first-line treatment strategies, and facilitate risk stratification for future clinical trials in patients with HR+ABC. Future validation of the proposed models in independent patient cohorts is warranted. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 3, 2021 Category: Cancer & Oncology Source Type: research

Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens
AbstractPurposeTo evaluate and compare health-related quality of life (HRQL) of women with early-stage breast cancer (BC) treated with different radiotherapy (RT) regimens.MethodsData were collected from five prospective cohorts  of BC patients treated with breast-conserving surgery and different RT regimens: intraoperative RT (IORT, 1 × 23.3 Gy;n = 267), external beam accelerated partial breast irradiation (EB-APBI, 10 × 3.85 Gy;n = 206), hypofractionated whole breast irradiation(hypo-WBI, 16 × 2.67 Gy;n&thinsp...
Source: Breast Cancer Research and Treatment - July 3, 2021 Category: Cancer & Oncology Source Type: research

Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis
ConclusionWe identify a novel subset of circulating tumor cell clusters that are enriched with stromal CAF cells in BC patient blood and preclinical mouse models of BC metastasis. Our data suggest that clustering of CTCs with cCAFs augments their metastatic potential and that CD44 might be an important mediator of heterotypic clustering of cCAFs and BC cells. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 3, 2021 Category: Cancer & Oncology Source Type: research

Psychological consequences of MRI-based screening among women with strong family histories of breast cancer
ConclusionNon-mutation carriers undergoing MRI-based screening had considerable baseline anxiety and cancer worry, although daily functioning was not impaired. Abnormal screens and biopsies did not appear to have adverse psychological effects. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 2, 2021 Category: Cancer & Oncology Source Type: research

Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer
ConclusionWe demonstrated that DOTBIS-derived measurements are modifiable with pre-surgical AKT inhibition and endocrine therapy, supporting further investigation of DOTBIS as a potential imaging assessment of response to neoadjuvant targeted therapies in early stage breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 2, 2021 Category: Cancer & Oncology Source Type: research

Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations
AbstractPurposeDiabetes Mellitus (DM) has been one of the well known risk factors of breast cancer (BC) development and also associated with adverse clinical outcomes of BC patients. Glucagon-like peptide-1 (GLP-1) receptor agonists have been used as antidiabetic therapeutic agents and recent epidemiological studies have reported their use to be correlated with increased BC risks. However, biological or pathological details have remained unknown. Therefore, in this study, we examined the status of GLP-1 receptor (GLP-1R) in BC with and without DM and correlated the findings with the clinicopathological factors of the patie...
Source: Breast Cancer Research and Treatment - July 2, 2021 Category: Cancer & Oncology Source Type: research

Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2 − negative breast cancer
AbstractWhile checkpoint inhibitors have been approved in patients with newly metastatic PDL1-positive triple negative breast cancer, similar clinical benefit with immunotherapy alone or in combination with chemotherapy has not been observed in patients with hormone receptor-positive, HER2 − negative breast cancer in the metastatic setting. However, in the ISPY2 trial, an increase in pathologic response has been observed with the addition of immunotherapy (± PARP inhibition) to chemotherapy compared to chemotherapy alone in patients with high-risk hormone receptor-positive, HER2− breast cancer. We...
Source: Breast Cancer Research and Treatment - July 2, 2021 Category: Cancer & Oncology Source Type: research

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
ConclusionsOral metronomic vinorelbine combined with trastuzumab is a well-tolerated and effective anti-tumor regimen for HER2-positive MBC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 1, 2021 Category: Cancer & Oncology Source Type: research

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase  II clinical trial
AbstractPurposeTo investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients.MethodsPatients in group A (aged  
Source: Breast Cancer Research and Treatment - June 25, 2021 Category: Cancer & Oncology Source Type: research

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
ConclusionsWe provide multi-faceted evidence that SP142 PDL1-positive TNBC have immuno-genomic features characterized as highly lymphocyte-infiltrated and a relatively favorable survival. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 25, 2021 Category: Cancer & Oncology Source Type: research

LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis
ConclusionSNHG6 promoted EMT and BC cell proliferation and migration by acting as a miR-543 sponge and disinhibiting LAMC1/PI3K/AKT pathway. SNHG6/miR-543/LAMC1 axis could serve as candidates for the development of therapeutic strategies for BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 25, 2021 Category: Cancer & Oncology Source Type: research

ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells
ConclusionsZEB1 could not only regulate EMT, but also inhibit GPX4 transcription by binding to the E-box motif. It was important to note that the ZEB1/GPX4 axis had a therapeutic effect on breast cancer metabolism. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 24, 2021 Category: Cancer & Oncology Source Type: research

Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
ConclusionWhile well tolerated with a strong preclinical rationale, the combination of ruxolitinib and trastuzumab did not lead to an improvement in PFS compared to historical control in patients with trastuzumab-resistant metastatic HER2+  breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 24, 2021 Category: Cancer & Oncology Source Type: research

Early reflector localization improves the accuracy of localization and excision of a previously positive axillary lymph node following neoadjuvant chemotherapy in patients with breast cancer
ConclusionThis study suggests a benefit of axillary lymph node reflector placement in the early NAC setting. Early reflector placement allows for more accurate excision of the CALN during axillary surgery after NAC as compared to placement of localization wires or reflectors in the few weeks prior to surgery. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 23, 2021 Category: Cancer & Oncology Source Type: research

Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers
ConclusionGiven the variability of treatment recommendations, and health care provider uncertainty around the benefits of therapies for VMS, more ‘real-world’ trials are needed to optimize patient care. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 22, 2021 Category: Cancer & Oncology Source Type: research

COVID-19 vaccination and breast cancer surgery timing
AbstractThere have been recent reports in the breast imaging literature of unilateral axillary lymphadenopathy following COVID-19 vaccination. It is unclear whether the reactive lymphadenopathy may impact the sentinel lymph node biopsy procedure. In this article, we provide guidelines regarding the timing of the COVID-19 vaccine and breast cancer surgery which were formulated after a review of the available literature and in consultation with infectious disease specialists. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 22, 2021 Category: Cancer & Oncology Source Type: research

Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study
ConclusionAmong patients with post-NAC residual TNBC, more than a quarter exhibited a detectable amount of ctDNA after curative surgery. The ctDNA VAF changed variably during the course of PORT. Therefore, ctDNA kinetics can serve as a biomarker for optimizing adjuvant treatment. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 21, 2021 Category: Cancer & Oncology Source Type: research

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial
ConclusionThe similarity of the time-to-event analyses between CT-P6 and trastuzumab supports the equivalence in terms of efficacy established for the primary endpoint. CT-P6 was well tolerated, with comparable safety and immunogenicity to trastuzumab.ClinicalTrials.gov: NCT02162667 (registered June 13, 2014) (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 20, 2021 Category: Cancer & Oncology Source Type: research

National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes
AbstractPurposePrevious studies have suggested axillary lymph node dissection (ALND) can be omitted in early breast cancer patients undergoing mastectomy with positive lymph nodes (LNs). We assessed the national utilization of ALND and overall survival (OS) for larger, locally advanced tumors in patients undergoing mastectomy with positive LNs.MethodsThe National Cancer Database from 2006 to 2016 was queried for mastectomy patients with clinical T3/T4, N0 tumors, and 1 –2 positive LNs. Trends and outcomes for ALND were compared to sentinel lymph node biopsy (SLNB) alone.ResultsThousand nine hundred and seventeen wome...
Source: Breast Cancer Research and Treatment - June 18, 2021 Category: Cancer & Oncology Source Type: research

Prognosis  of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case–control study
This study aimed to assess if a PABC diagnosis influences survival compared to non-PABC.MethodsA single-center record review was performed to identify PABC patients  diagnosed from January 2007 through June 2018. Two controls were matched to each PABC case by stage, immunohistochemical (IHC) subtype, age (± 3) and year of diagnosis (± 2). Disease-free survival (DFS) and overall survival (OS) were estimated with the Kaplan–Meier method and compared with the log-rank test. Multivariate analysis was used to assess the impact of PABC on outcomes.Results125 PABC patients (pregnant: 62; pos...
Source: Breast Cancer Research and Treatment - June 16, 2021 Category: Cancer & Oncology Source Type: research

Letter to the editor regarding: ‘Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis’
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 16, 2021 Category: Cancer & Oncology Source Type: research

Prognostic factors for residual occult disease in shave margins during partial mastectomy
ConclusionResidual occult disease was shown to be a frequent event in this analysis of lumpectomy with circumferential shave margins. Having a positive initial lumpectomy margin was predictive of ROD in a non-corresponding margin. Surgeons should consider not being selective in their shave margins or margin of re-excision if shave margins were not obtained in their initial surgery. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 16, 2021 Category: Cancer & Oncology Source Type: research

A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
ConclusionsThe 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11 –25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 15, 2021 Category: Cancer & Oncology Source Type: research

Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?
AbstractPurposeControversy remains regarding the optimal margin width for patients with ductal carcinoma in situ (DCIS) who undergo breast conserving surgery (BCS).MethodsWomen with a primary DCIS diagnosis were enrolled in a statewide population-based cohort from 1997 to 2006. Patients were surveyed every two years with follow-up data available through 2016. Surgical pathology reports were collected for 559 participants following breast conserving surgery. Multivariable Cox proportional hazard models evaluated relationships between locoregional recurrence (LRR) and margin width in the presence or absence of adjuvant radia...
Source: Breast Cancer Research and Treatment - June 15, 2021 Category: Cancer & Oncology Source Type: research

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
ConclusionThis is the first phase 3 trial of a trastuzumab biosimilar to report long-term survival data similar to originator trastuzumab in patients with MBC. The comparable long-term OS between the trastuzumab-dkst and originator trastuzumab groups further supports the similarity of trastuzumab-dkst with originator trastuzumab and establishes trastuzumab-dkst as a safe and effective treatment option for patients with HER2-positive MBC.ClinicalTrials.gov NCT02472964; 6/16/2015 (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 14, 2021 Category: Cancer & Oncology Source Type: research

Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study
ConclusionPABC patients may have poorer survival outcomes. Further prospective data are needed to optimise management of these patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 14, 2021 Category: Cancer & Oncology Source Type: research

Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa
AbstractPurposeAdvanced breast cancer (BC) at diagnosis is common in sub-Saharan Africa (SSA), including among women living with HIV (WLWH). In public hospitals across South Africa (SA), 10 –15% of women present with stage IV BC, compared to 
Source: Breast Cancer Research and Treatment - June 14, 2021 Category: Cancer & Oncology Source Type: research

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)
ConclusionAmenorrhea at 18  months was less likely in recipients of adjuvant T-DM1 than TH. Future studies are needed to understand how T-DM1 impacts risk of infertility and permanent menopause, and to assess amenorrhea rates when T-DM1 is administered after standard HER2-directed chemotherapy regimens. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 12, 2021 Category: Cancer & Oncology Source Type: research

Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer
ConclusionBaseline AUS could, to a large extent, identify ALNM; however, post-NACT, AUS was insufficient to determine remaining ALNM. Thus, our results support the surgical staging of the axilla post-NACT. Baseline tumor biomarkers and patient characteristics were predictive of axillary-pCR. Larger, multicenter studies are needed to evaluate the performance of AUS post-NACT. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 12, 2021 Category: Cancer & Oncology Source Type: research

Observations with alpelisib in older patients ( ≥ 65 year of age) with breast cancer in a non-clinical trial setting
This study focused on older patients ( ≥ 65 years of age) treated outside a clinical trial to gain further experience on how these under-studied patients do with this new agent.MethodsThis descriptive, multi-site study relied on medical record review.ResultsFifty-one older breast cancer patients were started on alpelisib between May 2019 and September 2020. The median age and number of comorbidities at alpelisib initiation was 71  years and 4, respectively. Thirty-five patients had stopped alpelisib (median time on drug 2.6 months (range: 
Source: Breast Cancer Research and Treatment - June 12, 2021 Category: Cancer & Oncology Source Type: research

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
ConclusionHigh FEN1 expression is linked to features of aggressive tumour behaviour and may play a role in the direct progression of DCIS to invasive disease. Further studies are warranted to evaluate its mechanistic roles in DCIS progression and prognosis. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 12, 2021 Category: Cancer & Oncology Source Type: research

Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies
ConclusionsRisk assessment for TIC should include cardiac imaging assessment and should incorporate prior anthracycline use, the strongest risk factor for TIC. Screening and prediction of cardiotoxicity, referral to a cardio-oncology specialist, and initiation of effective prophylactic therapy may all improve prognosis in patients receiving HER2-directed therapy. Beta blockers and ACE inhibitors appear to mitigate risk of TIC. Anthracycline-free regimens have been proven to be efficacious in early HER2-positive breast cancer and should now be considered the standard of care for early HER2-positive breast cancer. Newer HER2...
Source: Breast Cancer Research and Treatment - June 11, 2021 Category: Cancer & Oncology Source Type: research